Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...
While you can just use certain console commands above to adjust your bank balance, there's also an infinite money cheat that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback